Therapy Areas: Diabetes
Innovent and Ollin report progress in development of OLN324 (IBI324)
18 September 2025 - Chinese biopharmaceutical company Innovent Biologics Inc (HKEX:01801) and its US partner Ollin Biosciences on Thursday announced a clinical update on IBI324 (Ollin R&D code: OL...
Alteogen secures European Commission approval for aflibercept biosimilar EYLUXVI
17 September 2025 - South Korean biopharmaceutical company Alteogen Inc. (KOSDAQ:196170) announced on Wednesday that the European Commission has granted marketing authorisation for EYLUXVI (ALT-L9), a...
Eli Lilly and Company's orforglipron outperforms oral semaglutide in Phase 3 ACHIEVE-3 trial
17 September 2025 - Medicine firm Eli Lilly and Company (NYSE: LLY) on Wednesday reported positive topline results from ACHIEVE-3, a Phase 3, 52-week trial comparing the oral GLP-1 receptor agonist or...
Ascletis presents ASC30 study results at EASD Annual Meeting
17 September 2025 - Chinese pharmaceutical company Ascletis Pharma Inc (HKEX:1672) has announced that results from cohorts 1 and 2 of 28-day multiple ascending dose (MAD) study of its oral small molec...
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
15 September 2025 - Biotechnology company Kodiak Sciences Inc (Nasdaq: KOD) announced on Monday that new data from its Phase 1b APEX study of KSI-101 showed rapid and clinically meaningful vision gain...
Renalytix signs collaboration agreement with Tempus AI to expand KidneyIntelX.dkd access
15 September 2025 - Precision medicine diagnostics company Renalytix plc (LSE: RENX) (OTCQB: RNLXY) announced on Monday that it has entered a definitive collaboration agreement with technology company...